Altogether, our studies indicate that CD44 contributes to increased doxorubicin chemoresistance in osteosarcoma, by positive regulation of MDR1 expression and its effects on apoptosis-regulatory proteins, including members of the p53-pathway. Here, CD44 is linked to osteosarcoma.